Last reviewed · How we verify
Quadrivalent influenza GSK2282512A vaccine
Quadrivalent influenza GSK2282512A vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of influenza disease caused by four different strains of the influenza virus.
This quadrivalent influenza vaccine stimulates the body's immune system to produce antibodies against four different influenza viruses.
This quadrivalent influenza vaccine stimulates the body's immune system to produce antibodies against four different influenza viruses. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | Quadrivalent influenza GSK2282512A vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza viruses that are not capable of causing disease. When administered, the vaccine triggers an immune response, producing antibodies that can recognize and neutralize the influenza viruses, providing protection against infection.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children (PHASE3)
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (PHASE3)
- A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent influenza GSK2282512A vaccine CI brief — competitive landscape report
- Quadrivalent influenza GSK2282512A vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Quadrivalent influenza GSK2282512A vaccine
What is Quadrivalent influenza GSK2282512A vaccine?
How does Quadrivalent influenza GSK2282512A vaccine work?
What is Quadrivalent influenza GSK2282512A vaccine used for?
Who makes Quadrivalent influenza GSK2282512A vaccine?
What development phase is Quadrivalent influenza GSK2282512A vaccine in?
What are the side effects of Quadrivalent influenza GSK2282512A vaccine?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza disease caused by four different strains of the influenza virus
- Compare: Quadrivalent influenza GSK2282512A vaccine vs similar drugs
- Pricing: Quadrivalent influenza GSK2282512A vaccine cost, discount & access